Discussion
Drug maker Servier announced that it is discontinuing development of its oral treatment candidate sevasemten for both Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). The announcement comes just days after top-line data, or the first results of a clinical trial, showed that sevasemten had…